Aa
A
A
Close
Avatar_universal
improved hbsag loss to 29.61% by pegintf+nucs 120weeks
http://www.natap.org/2013/EASL/EASL_70.htm

Program Abstract

Aims: To investigate the improved HBsAgresponse in chronic hepatitis B (CHB) patients treated with prolonged peginterferon α-2a combined with nucleos(t)ide analogue.

Methods: One hundred and fifty-two CHB patients treated with peginterferon α-2a plus nucleos(t)ide analogue from Jan 2007 to Sep 2012 were retrospectively investigated. The mean treatment duration was 79 weeks (range 24-120 weeks). Serum HBsAglevels at baseline, week 12, 24, 36, 48, 72, 96 and 120 of treatment were detected

Results: The cumulative HBsAgloss rates of patients treated at 48-week, 96-week and 120-week with peginterferon α-2a plus nucleos(t)ide analogue were 8.55% (13/152), 26.97% (41/152) and 29.61% (45/152), respectively. The time to HBsAgloss was 74.93±27.21 weeks. Most HBsAgloss occurred during week 49-96. The HBsAglevel at week 12 of treatment in 45 patients who obtained HBsAgloss was 1.91±1.27log10IU/mL, which was significantly lower than baseline (3.22±0.82log10IU/mL) (t=5.759, P< 0.01). However, the HBsAglevel at baseline in 107 patients who did not obtain HBsAgloss was 3.57±0.96 log10 IU/mL and HBsAglevels reduction at week 12, 24, 48, 96 and 120 were 0.24±0.38, 0.45±0.60, 0.83±0.84, 1.29±1.05 and 1.66±1.66 log10IU/ml, respectively (Figure 1). As expected, the HBsAglevel at week 12 of treatment was not significantly different from that at baseline in this group of patients (t=1.529, P=0.128), while that at week 96 was significantly decreased compared with week 48 (t=2.166, P=0.033).

Conclusion: Prolonged peginterferon α-2a combined with nucleos(t)ide analogue treatment could increase the cumulative HBsAgloss rate. In patients who do not obtain HBsAgloss, prolonged therapy could reduce the HBsAglevel and improve the anti-viral response. The reduction of HBsAglevel of week 12 from baseline could be a predictor of HBsAgclearance
Cancel
8 Answers
Page 1 of 1
Avatar_universal
very very important that the most hbsag decrease or response to pegintf+nucs was on 49-96weeks

this means the routine treatment of 48weeks is wrong, another study also showed that the max effect on immune system by pegintf is after 48weeks
Comment
Cancel
Avatar_universal
Comment
Comment
Submit Comment
Avatar_universal
another consideration: sequential treatment response is still the best even at 48weeks combo add on

pgintf+nucs 120weeks 29.61% hbsag loss
nucs long term 3-7years and then pegintf add on 48weeks 50% hbsag loss
Comment
Cancel
Avatar_universal
Comment
Comment
Submit Comment
Avatar_universal
I was told NO many times to my requests for this type of treatment. They are butchering us here. :(  only damn nucs is all they prescribe.

Listen to this what I am told. That they dont give interferon to people with undetectable DNA apparently according to US standards that insurance companies have in place for them.
Comment
Cancel
Avatar_universal
Comment
Comment
Submit Comment
Avatar_universal
I sure would like to see gamma interferon results. In comparison to this.
Comment
Cancel
Avatar_universal
Comment
Comment
Submit Comment
1024307_tn?1292002086
nucs long term 3-7years and then pegintf add on 48weeks 50% hbsag loss



This is something!
Is the 50% HBsAg loss in both cases: HBeAg positive and negative?
50% -that's high.
Comment
Cancel
1024307_tn?1292002086
Comment
Comment
Submit Comment
Avatar_universal

yes
Comment
Cancel
Avatar_universal
Comment
Comment
Submit Comment
Avatar_universal
i mean after 3-7years on nucs you get hbeag negative anyway....
Comment
Cancel
Avatar_universal
Comment
Comment
Submit Comment
Avatar_universal
and the point is not hbeag, it doesn t matter, it is hbsag decline that matters
Comment
Cancel
Avatar_universal
Comment
Comment
Submit Comment
Your Answer
Avatar_universal
Answer
Know how to answer? Tap here to leave your answer...
Answer
improved hbsag loss to 29.61% by pegintf+nucs 120weeks
Submit Answer
A
A
Blank
Weight Tracker
Weight Tracker
Start Tracking Now
Hepatitis B Community Resources